Bortezomib is active in patients with untreated or relapsed Waldenström's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group

Christine I. Chen, C. Tom Kouroukis, Darrell White, Michael Voralia, Edward Stadtmauer, A. Keith Stewart, John J. Wright, Jean Powers, Wendy Walsh, Elizabeth Eisenhauer

Research output: Contribution to journalArticlepeer-review

173 Citations (Scopus)
Original languageEnglish
Pages (from-to)1570-1575
Number of pages6
JournalJournal of Clinical Oncology
Volume25
Issue number12
DOIs
Publication statusPublished - Apr 20 2007
Externally publishedYes

ASJC Scopus Subject Areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Bortezomib is active in patients with untreated or relapsed Waldenström's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group'. Together they form a unique fingerprint.

Cite this

Chen, C. I., Kouroukis, C. T., White, D., Voralia, M., Stadtmauer, E., Stewart, A. K., Wright, J. J., Powers, J., Walsh, W., & Eisenhauer, E. (2007). Bortezomib is active in patients with untreated or relapsed Waldenström's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 25(12), 1570-1575. https://doi.org/10.1200/JCO.2006.07.8659